BioPharma Dive

@BioPharmaDive

We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma. Sign up here:

Washington, D.C.
Vrijeme pridruživanja: srpanj 2013.

Tweetovi

Blokirali ste korisnika/cu @BioPharmaDive

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioPharmaDive

  1. 31. sij

    With $420M in Q4 revenues, 's cystic fibrosis drug Trikafta performed 5x better than expected — and capped off an 8-year growth story for the biotech's CEO.

    Poništi
  2. 31. sij

    Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO.

    Poništi
  3. 31. sij

    Competition is heating up for copycats to 's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting

    Poništi
  4. proslijedio/la je Tweet
    31. sij

    If you haven't yet, check out 's latest deep dive. After years being all-in on brain drugs, big pharma pulled back. Is a return on the horizon? And, if so, what effects might it have on drug research?

    Prikaži ovu nit
    Poništi
  5. 30. sij

    Spinraza rivals and Tecfidera patent challenges were in the spotlight as provided few details about its planned filing for aducanumab.

    Poništi
  6. 30. sij

    's top scientist, however, set low expectations the drug will show a clear benefit.

    Poništi
  7. 29. sij

    Biotech execs see a new era of neuroscience advances ahead. But it's hard to pinpoint what would cause pharma to dive back in — and what ripples that would create.

    Poništi
  8. 29. sij

    The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.

    Poništi
  9. 29. sij

    Another 100 infants received ' Zolgensma in the fourth quarter, supported by broad insurance coverage and more newborn screening.

    Poništi
  10. proslijedio/la je Tweet
    29. sij
    Poništi
  11. 17. sij

    The pharma is targeting deals between $1 billion and $5 billion every quarter, its CFO told Reuters, although the focus will be on clinical-stage assets

    Poništi
  12. 17. sij

    An upcoming FDA advisory meeting will be a key test for Intercept's ambitions to become the first drugmaker with an approved therapy for the liver disease

    Poništi
  13. proslijedio/la je Tweet
    16. sij

    "Are you all on Vascepa?" asked CEO John Thero to a room full of investors Wednesday ... Check out and 's last dispatch from for more:

    Poništi
  14. 15. sij

    At predicted its crown jewel - a Pompe disease drug - has opportunity for $1B to $2B in peak sales

    Poništi
  15. 15. sij

    After a decade of research, said it will withdraw its application for oxycodegol and make no further investment in the drug.

    Poništi
  16. 15. sij

    Andelyn Biosciences, named after two children treated with gene therapy at , will operate as a for-profit subsidiary of the Ohio-based hospital.

    Poništi
  17. 15. sij

    Though is tied to a 10-year, $5B research pact with , its CEO says there's still some "wheeling and dealing" left to do.

    Poništi
  18. proslijedio/la je Tweet
    15. sij

    The 2020s will be neuroscience's decade, Roche's Bill Anderson bullishly predicted Tuesday at , which featured other updates from and

    Poništi
  19. 14. sij

    M&A hopes might have fizzled, but the first day of still had meaningful updates for several companies including , , and

    Poništi
  20. 13. sij

    A quiet start to , often viewed as a gauge of dealmaking interest, could spark some doubts, however.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·